Title:
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (CEMI-first) - An Open Label, Single Arm, Prospective Phase II Trial of the DeCOG Network
Phase:
II
Contact:
Angela Diana Klein / Kontaktperson
Clinical Investigator:
Prof. Dr. med. Jessica Hassel
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT06981325
EU CTIS/EudraCT:
Keine Registernummer angegeben. N/A:
